Floatz logo

Dilatrend

Essential Hypertension

Chong Kun Dang PharmaceuticalPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Essential Hypertension cohort.

Asset / SponsorPhaseRating
Hydrochlorothiazide
Yuhan Corporation
Phase 4BBB
AMLODIPINE
Yuhan Corporation
Phase 4BBB
Dapagliflozin
University of Campinas, Brazil
Phase 4BB
LABETALOL
ProMedica Health System
Phase 3BB
VALSARTAN
ARKAY Therapeutics
Phase 4BB

View all 44 →

Same molecule, other indications

Dilatrend is also rated in:

coronary artery disorderDormant
CC
Indicative ·
47 / 100
View asset →
congestive heart failureDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →